Celgene's Oral REVLIMID Plus Dexamethasone Given Approval to Treatment Patients with Newly Diagnosed Multiple Myeloma in Japan

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation CELG today announced that REVLIMID® (lenalidomide), a cancer medicine that is administered orally, has been granted full marketing authorization by Japan's Ministry of Health, Labour and Welfare (MHLW) for use in combination with dexamethasone as a treatment for patients newly diagnosed with multiple myeloma. This marketing authorization expands upon the approval of REVLIMID in 2010 for the treatment of patients with relapsed or refractory multiple myeloma. "The approval of REVLIMID as an option for use in newly diagnosed patients with multiple myeloma represents an important step forward in the interest of patients, health care and society," said Joe Melillo, VP See full press release